Clinical Trial Update: EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating an EGFR-TKI with chemotherapy in non-small cell lung cancer patients who have both an EGFR mutation and BIM deletion polymorphis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKI (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non-Small-Cell Lung Cancer | Phase 3 | Status: UNKNOWN